Deep Dive

Primoris builds the unglamorous backbone of the electricity build-out — gas and electric utility distribution, transmission, communications, and the EPC work behind power plants and data centers — and ran nearly 3x to a $205 peak before one botched renewables-execution quarter cut the stock in half in a single day. The durable Utilities engine kept growing; a fixed-price solar portfolio blew up. The question is whether a contained, fixable problem just handed you a grid-and-data-center franchise at ~13x EBITDA.

Netflix is the one company that unambiguously won streaming — ~$45B of revenue growing mid-teens, ~30% operating margins, ~$9.5B of free cash flow, and ~$9B a year in buybacks. Yet the stock has fallen ~41% from its high to near a 52-week low as the market re-rated streaming and growth names and a wave of industry consolidation (Fox's $22B Roku deal) raised an uncomfortable question: is Netflix being pulled from its 'build, don't buy' discipline into expensive M&A? The fundamentals didn't break. The multiple did — from a premium to ~20-25x forward earnings.

Abacus has more than doubled off its $4.60 low by turning a niche, capital-intensive life-settlements book — buying life insurance policies and collecting the death benefit — into a fast-growing specialty financial, with FY2025 revenue up 110% to $235M. The next leg of the story is a pivot away from the leveraged balance sheet toward capital-light fee income: a stake in Manning & Napier (~$18B AUM) and LifeARC, an AI lifespan-modeling platform. The catch: GAAP EPS of $0.36 sits a fork away from the Street's ~$1.00 adjusted number, and interest coverage is only ~2x.

Vertex runs the indirect-tax engine inside the world's ERP systems — sales tax, VAT, and now e-invoicing determination wired into SAP, Oracle, and Workday, where a wrong rate means an audit. The business kept growing (~12% in FY2025, a Q1 FY2026 beat-and-raise, expanding margins), but the stock fell ~70% from $40 to ~$12 in the SaaS de-rating and an AI-disruption scare. At ~2.6x EV/sales and ~15x forward adjusted earnings, a lot of bad news is priced in — the open question is whether low-teens growth and the global e-invoicing mandate wave are enough to re-rate it.

Axon has compounded revenue at ~34% for five years, building a hardware-plus-cloud flywheel — TASER, body cameras, Evidence.com, and now AI report-writing and counter-drone — with ~125% net revenue retention and a moat the competition can't bolt on. The 'SaaSpocalypse' cut the stock in half from $886 to ~$442, and the fundamentals never flinched. The catch: even halved, it's 12x sales, and ~23% of revenue goes out the door as stock comp.

Clorox has clawed gross margin back from a 36% wartime trough to ~45% and rebuilt EPS from $1.21 to $6.56 — but revenue has sat at ~$7.1B for five straight years, and a sudden CEO exit just reintroduced the one risk a slow-growth compounder can't easily absorb. At a ~5% yield and ~15x earnings, the income is the thesis; the growth is the question.

NICE is the profitable leader in cloud contact-center and financial-crime software — ~66% gross margins, ~$700M free cash flow, net cash, buying back ~9% of its float a year — trading at ~9x earnings and a ~13% FCF yield because the market is convinced agentic AI will obsolete the per-seat contact center. The whole investment case is one question: does AI grow NICE's pie or eat its seats? At this price, you're barely paying to find out.

Globant went from a 30%-plus digital-engineering compounder to ~2% growth in a single year, and the stock fell ~61% from $97 to ~$37 as the market priced two fears at once: that client tech spending froze, and that generative AI commoditizes the headcount-billed services model entirely. It now trades at 0.77x sales, ~5.5x EBITDA, and a ~16% free-cash-flow yield — distressed multiples for a profitable, cash-generative, founder-led firm. The question is whether the growth stall is cyclical or the first sign of obsolescence.

ServiceTitan is building an unassailable vertical OS for a $657B trades industry that is structurally under-digitized. With 95%+ gross retention, expanding AI monetization, and a credible path to 20%+ FCF margins, the stock deserves a re-rate as the Rule of 40 improves.

Toast is the best-positioned pure-play in restaurant technology — real switching costs, a data moat that compounds with every location added, and an AI layer making the platform stickier. At $24.64 — 50% off its highs — you're paying 2x sales for a business that just turned profitable and is growing 24% annually.

MRVL's +219% YTD run and June 2 gap to $290 reflect a genuine business inflection: Marvell is becoming the custom silicon backbone of hyperscale AI infrastructure. With 20+ ASIC design wins entering production in FY2028-2029, a $2B Nvidia strategic investment, and accelerating revenue growth guided at 35% YoY for Q2 FY27, the fundamental case is real. At 65x forward P/E, the stock is pricing in execution — and at this level, there is zero tolerance for slippage.

INTU has collapsed 57% from its 52-week high on a TurboTax pricing miss and securities fraud ambulance-chasing. Under the noise: $7.5B in annual free cash flow, 80%+ gross margins, a dominant SMB accounting platform, and a 12-15% revenue growth engine. At an 8% FCF yield — the cheapest INTU has been in a decade — the market is pricing in an AI apocalypse that the numbers don't support.

GKOS has a dominant MIGS franchise, a corneal health business growing 40%+, and a just-launched product that could redefine keratoconus care. At $103 — 31% below the 52-week high and 31% below consensus — the pullback is pricing in failure that the fundamentals don't support.

Micron's HBM4 ramp has turned the memory cycle into a structural AI story — 74.9% gross margins and a $1,113 fair value make this one of the better risk/reward setups in semis.

ASML holds the only monopoly that matters in AI — the machine that makes every leading-edge chip on earth. At $1,606, you're paying full price for an undeniable position.

TI's capex supercycle is ending and FCF is set to ramp toward $8+/share — but at $324, you're paying for the recovery before it arrives.

AMD: Strong thesis, weak entry price. At 54x forward earnings, the risk/reward is no longer asymmetric.